IP Library › Granted Patent US 12,157,877
Granted Patent B2
US 12,157,877 · App. 16/092,482 · Granted Dec 3, 2024

Cell retention device and method

Inventors: Jonathan Coffman (Union City, CA); Scott Godfrey (Pleasanton, CA); Samantha Wang (San Francisco, CA)
Assignee: Boehringer Ingelheim International GmbH
C12M29/10C12M29/16C12M47/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,157,877
App. No.
16/092,482
Granted
Dec 3, 2024
Kind
B2
Abstract

The subject technology relates to a cell retention device and method for use in a perfusion cell culture system where the cell retention device includes a hollow-fiber filter having an average pore size ranging from about 0.5 to about 20 μm and having the ability to operate under perfusion cell culture conditions for up to 35 days without being clogged or losing its product sieving ability by more than 20%.

Claims (8)

1. A method for harvesting a recombinant monoclonal antibody from a perfusion culture vessel, said method comprising the steps of:

a. culturing Chinese Hamster Ovary (CHO) cells expressing the recombinant monoclonal antibody in a perfusion culture in the perfusion culture vessel;

b. subjecting the cell culture fluid of the perfusion culture vessel to a tangential flow filtration system comprising a hollow-fiber filter having an average pore size ranging from about 5 to about 8 microns, wherein the hollow-fiber filter has a filter capacity of 1,000 to 10,000 L/M 2 ,

and wherein the hollow-fiber filter can retain at least 90% of its product sieving ability until the total volume of filtrate per m 2 of the hollow-fiber filter is greater than or equal to 1000 L/m 2 when the cell retention device is configured to run in tangential-flow filtration (TFF) perfusion mode;

collecting the filtrate from the hollow fiber filter, wherein the filtrate comprises the recombinant monoclonal antibody; and

d. recirculating the remaining cell culture fluid to the perfusion culture vessel.

2. The method of claim 1 , wherein the cell retention device is external to the perfusion cell culture vessel.

3. The method of claim 1 , wherein the hollow-fiber filter can retain at least 90% of its product sieving ability after 35 days when the cell retention device is configured to run in tangential-flow filtration (TFF) perfusion mode.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2019
From: COFFMAN, JONATHAN; GODFREY, SCOTT; WANG, SAMANTHA
To: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Reel/Frame 048934/0812 →
Continuity (3)
Provisional Application 62330912 · May 3, 2016
Provisional Application 62322825 · Apr 15, 2016
Related Publication 20190169559A1 · Jun 6, 2019